DZ2788A1 - Selective IL-2 agonists and antagonists. - Google Patents

Selective IL-2 agonists and antagonists.

Info

Publication number
DZ2788A1
DZ2788A1 DZ990088A DZ990088A DZ2788A1 DZ 2788 A1 DZ2788 A1 DZ 2788A1 DZ 990088 A DZ990088 A DZ 990088A DZ 990088 A DZ990088 A DZ 990088A DZ 2788 A1 DZ2788 A1 DZ 2788A1
Authority
DZ
Algeria
Prior art keywords
agonists
antagonists
selective
Prior art date
Application number
DZ990088A
Other languages
French (fr)
Inventor
Armen B Shanafelt
Jeffrey M Greve
Jesmok Gary
Kenneth J Lembach
Gayle D Wetzel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DZ2788A1 publication Critical patent/DZ2788A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DZ990088A 1998-05-15 1999-05-12 Selective IL-2 agonists and antagonists. DZ2788A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
DZ2788A1 true DZ2788A1 (en) 2003-12-01

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990088A DZ2788A1 (en) 1998-05-15 1999-05-12 Selective IL-2 agonists and antagonists.

Country Status (39)

Country Link
EP (1) EP1076704B1 (en)
JP (1) JP4276783B2 (en)
KR (1) KR100607609B1 (en)
CN (2) CN100366742C (en)
AR (1) AR020322A1 (en)
AT (1) ATE351907T1 (en)
AU (1) AU759697B2 (en)
BG (1) BG65139B1 (en)
BR (1) BRPI9910504B1 (en)
CA (1) CA2327349C (en)
CO (1) CO5070701A1 (en)
CU (2) CU23273B7 (en)
CY (1) CY1107533T1 (en)
CZ (1) CZ302071B6 (en)
DE (1) DE69934881T2 (en)
DK (1) DK1076704T3 (en)
DZ (1) DZ2788A1 (en)
ES (1) ES2281175T3 (en)
HK (1) HK1039963B (en)
HN (1) HN1999000075A (en)
HU (1) HU226142B1 (en)
IL (2) IL139136A0 (en)
MY (1) MY130274A (en)
NO (1) NO329235B1 (en)
NZ (1) NZ508098A (en)
PA (1) PA8472601A1 (en)
PE (1) PE20000475A1 (en)
PL (1) PL201675B1 (en)
PT (1) PT1076704E (en)
RO (1) RO122150B1 (en)
RU (1) RU2235729C2 (en)
SI (1) SI20643B (en)
SK (1) SK288100B6 (en)
SV (1) SV1999000061A (en)
TN (1) TNSN99090A1 (en)
TR (1) TR200003354T2 (en)
TW (1) TWI223663B (en)
UA (1) UA73719C2 (en)
WO (1) WO1999060128A1 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
AU4057300A (en) 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
KR20030064275A (en) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
PT1366067E (en) 2001-03-07 2012-11-29 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP4309662B2 (en) 2001-05-03 2009-08-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Tumor-specific recombinant antibodies and uses thereof
CN100390282C (en) 2001-12-04 2008-05-28 默克专利有限公司 Immunocytokines with modulated selectivity
EP1572748B1 (en) 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
EP1925626A1 (en) 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
DE602004031341D1 (en) 2003-07-21 2011-03-24 Transgene Sa MULTIFUNCTIONAL CYTOKINE
DK1682180T3 (en) 2003-11-04 2010-01-11 Novartis Vaccines & Diagnostic Monoclonal antagonist anti-CD40 antibodies and methods for their use
US7858081B2 (en) * 2004-02-27 2010-12-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) IL-15 mutants having agonists/antagonists activity
CA2557677A1 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN101244261B (en) * 2008-03-10 2010-09-15 山东大学 A kind of biological preparation containing unrefolded recombinant protein and its preparation method and application
DE102008023820A1 (en) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
JP5766124B2 (en) 2009-01-21 2015-08-19 アムジェン インコーポレイテッド Compositions and methods for the treatment of inflammatory and autoimmune diseases
CN102101885B (en) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 Human interleukin-II mutant of low-inductivity suppressor T cells and use thereof
PL2637694T3 (en) 2010-11-12 2021-10-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CU23923B1 (en) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
PL3489255T3 (en) 2011-02-10 2021-11-22 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
EA034350B1 (en) 2014-02-06 2020-01-30 Ф.Хоффманн-Ля Рош Аг Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106659757B (en) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 Superagonists, partial agonists and antagonists of interleukin 2
MA40094B1 (en) 2014-08-06 2022-05-31 Univ Miami Interleukin-2/interleukin-2 alpha receptor fusion proteins and methods of use
SG11201700629TA (en) * 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2016335860B2 (en) 2015-10-08 2023-08-10 Nektar Therapeutics Combination of an IL-2Rbeta-selective agonist and a long-acting IL-15 agonist
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7422480B2 (en) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド Interleukin-2 mutant protein for regulatory T cell proliferation
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN116903741A (en) 2016-06-20 2023-10-20 科马布有限公司 Antibodies or antigen binding fragments thereof that specifically bind to PD-L1 and uses thereof
CA3028829A1 (en) * 2016-06-22 2017-12-28 David Klatzmann Genetically modified t lymphocytes
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
BR122020025384B1 (en) * 2016-12-13 2022-07-12 Delinia, Inc FUSION PROTEINS AND DIMERIC, USES OF THEM AND PHARMACEUTICAL COMPOSITION
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020520665A (en) 2017-05-24 2020-07-16 ノバルティス アーゲー Antibody-cytokine grafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (en) * 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
CN111107868A (en) * 2017-05-24 2020-05-05 诺华股份有限公司 Antibody cytokine graft protein and method of use
WO2018234862A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF
MX2020001336A (en) * 2017-08-03 2020-08-20 Synthorx Inc CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES.
PH12020550661A1 (en) * 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
MA51291A (en) 2017-12-19 2020-10-28 Xencor Inc MODIFIED IL-2 FC FUSION PROTEINS
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
IL308797A (en) 2018-03-28 2024-01-01 Ascendis Pharma Oncology Div A/S IL-2 conjugates
TWI853807B (en) 2018-03-28 2024-09-01 美商必治妥美雅史谷比公司 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
EP3827014A1 (en) * 2018-07-24 2021-06-02 BioNTech RNA Pharmaceuticals GmbH Il2 agonists
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
ES2985387T3 (en) 2018-09-17 2024-11-05 Gi Innovation Inc Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
AU2019343251B2 (en) 2018-09-21 2022-06-09 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin 2 and use thereof
WO2020125743A1 (en) 2018-12-21 2020-06-25 江苏恒瑞医药股份有限公司 Human interleukin-2 variant or derivative thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
TW202115105A (en) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Il2 agonists
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
BR112022002666A2 (en) * 2019-08-13 2022-08-09 Amgen Inc INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF REGULATORY T CELLS
CA3159468A1 (en) 2019-12-12 2021-06-17 David Klatzmann Interleukin 2 chimeric constructs
PE20221506A1 (en) 2019-12-17 2022-10-04 Amgen Inc DUAL INTERLEUKIN-2/TNF RECEPTOR AGONIST FOR USE IN THERAPY
WO2021140416A2 (en) 2020-01-10 2021-07-15 Bright Peak Therapeutics Ag Modified il-2 polypeptides and uses thereof
KR20220127866A (en) * 2020-01-14 2022-09-20 신테카인, 인크. IL2 Mutein
KR20240046306A (en) 2020-01-14 2024-04-08 신테카인, 인크. Biased il2 muteins methods and compositions
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CN115698052A (en) 2020-03-19 2023-02-03 信达生物制药(苏州)有限公司 Interleukin 2 mutants and uses thereof
MX2022011893A (en) 2020-03-31 2022-10-18 Hanmi Pharm Ind Co Ltd Novel immunoactive interleukin 2 analog.
KR20230019889A (en) 2020-06-03 2023-02-09 아센디스 파마 온콜로지 디비전 에이/에스 IL-2 sequences and uses thereof
CN114507643A (en) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell derivative for expressing IL-2 and application thereof
AU2021369823A1 (en) 2020-10-29 2023-06-01 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
CN113308477A (en) * 2021-04-08 2021-08-27 华南农业大学 Eukaryotic expression recombinant plasmid of duck IL-2 gene and preparation method thereof
US20240391973A1 (en) 2021-09-22 2024-11-28 Fortvita Biologics (Singapore) Pte. Ltd. Interleukin-2 mutant and fusion protein thereof
US20240376172A1 (en) 2021-10-06 2024-11-14 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
CN114875069B (en) * 2022-04-22 2023-09-15 四川大学 Recombinant vector of genetically modified IL2 cytokine, host cell and application thereof
TW202413442A (en) * 2022-06-16 2024-04-01 美商希佛隆有限責任公司 Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
IL319435A (en) 2022-09-12 2025-05-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Interleukin-2 for use in treating autism spectrum disorder
FR3140287B1 (en) 2022-10-03 2025-11-21 Arkema France PROCESS FOR GRANULATING AZO COMPOUNDS AND OBTAINING GRANULES
EP4631972A1 (en) 2022-11-18 2025-10-15 Nanjing Novoacine Biotechnology Co., Ltd. Site-specific coupled pegylated interleukin-2 mutant with receptor affinity preference and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003334C1 (en) * 1988-07-26 1993-11-30 Хем Рисерч, Инк, (US) Method for treatment of patients having tumors
FR2684878B1 (en) * 1991-12-12 1994-02-11 Roussel Uclaf STABILIZED PHARMACEUTICAL COMPOSITION OF RECOMBINANT, NON-GLYCOSYLATED HUMAN IL2 IN REDUCED FORM AND PROCESS FOR PREPARING THE SAME.
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
HU226142B1 (en) 2008-05-28
JP4276783B2 (en) 2009-06-10
SK288100B6 (en) 2013-07-02
HK1039963B (en) 2008-09-05
SK17242000A3 (en) 2001-07-10
PL344407A1 (en) 2001-11-05
CN101319247B (en) 2012-12-12
EP1076704A1 (en) 2001-02-21
ATE351907T1 (en) 2007-02-15
BRPI9910504B1 (en) 2016-08-09
RO122150B1 (en) 2009-01-30
CA2327349A1 (en) 1999-11-25
AU4078499A (en) 1999-12-06
TNSN99090A1 (en) 2005-11-10
AU759697B2 (en) 2003-04-17
IL139136A (en) 2009-05-04
RU2235729C2 (en) 2004-09-10
CZ302071B6 (en) 2010-09-29
HN1999000075A (en) 1999-09-29
IL139136A0 (en) 2001-11-25
SI20643B (en) 2008-02-29
KR20010043602A (en) 2001-05-25
DE69934881T2 (en) 2007-11-08
TWI223663B (en) 2004-11-11
HK1039963A1 (en) 2002-05-17
CN100366742C (en) 2008-02-06
MY130274A (en) 2007-06-29
NO20005762D0 (en) 2000-11-14
CY1107533T1 (en) 2013-03-13
CZ20004213A3 (en) 2001-05-16
AR020322A1 (en) 2002-05-08
BG104929A (en) 2001-09-28
SV1999000061A (en) 2000-03-14
UA73719C2 (en) 2005-09-15
JP2002515247A (en) 2002-05-28
PL201675B1 (en) 2009-04-30
PE20000475A1 (en) 2000-07-07
DK1076704T3 (en) 2007-03-12
CU23273B7 (en) 2008-04-09
NO20005762L (en) 2001-01-11
TR200003354T2 (en) 2001-03-21
BG65139B1 (en) 2007-03-30
CU23272A1 (en) 2008-04-09
EP1076704B1 (en) 2007-01-17
CN101319247A (en) 2008-12-10
KR100607609B1 (en) 2006-08-02
PT1076704E (en) 2007-02-28
CN1309705A (en) 2001-08-22
HUP0101948A2 (en) 2001-09-28
CO5070701A1 (en) 2001-08-28
NO329235B1 (en) 2010-09-20
ES2281175T3 (en) 2007-09-16
HUP0101948A3 (en) 2003-08-28
WO1999060128A1 (en) 1999-11-25
CA2327349C (en) 2010-10-26
SI20643A (en) 2002-02-28
BR9910504A (en) 2001-01-09
NZ508098A (en) 2003-09-26
PA8472601A1 (en) 2000-09-29
DE69934881D1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
DZ2788A1 (en) Selective IL-2 agonists and antagonists.
TR199900531A3 (en) Pirazolopyrimidines and pirazolotriazines.
NL1008254A1 (en) Test devices.
PT915846E (en) 2-SUBSTITUTED AND 2,5-SUBSTITUTED PHENYLCETOENOIS
DE69912677D1 (en) monitor
IT250621Y1 (en) TEST PROCEDURES, DEVICES AND TEST EQUIPMENT
FR2780857B1 (en) PESTICIDE AGENT
ATE310721T1 (en) AROMATIC C16-C20-SUBSTITUTED TETRAHYDRO-PROSTAGLANDINS USABLE LIKE FP AGONISTS
DE69932782D1 (en) bearing device
NO20003449D0 (en) centralization device
IS4947A (en) Troafloxacin mesylate tablet
NO20010804D0 (en) Muscarinic agonists and antagonists
TR199800117A3 (en) Isaksazol- and crotonacitamide derivatives and their use.
DE69921110D1 (en) DRILLING LIQUIDS AND ADDITIVES
DE69840421D1 (en) PARTICIPANTS CONTEXT
IT1295221B1 (en) GUMMATOR DEVICE.
NO990717D0 (en) Monitor st ° ttemekanisme
DE69912593D1 (en) seating device
LT99065A (en) BEARING DEVICE
ES1043504Y (en) TELEPHONE ADAPTER.
DE69903916D1 (en) EVALUATE TEXT UNITS
IT1291240B1 (en) GUMMATOR DEVICE.
ITFO980009U1 (en) ANTI-BRUSHING DEVICE.
ES1040736Y (en) EBOOK.
ES1041486Y (en) SOUND DEVICE FOR WRIST.